United Therapeutics Corp
UTHR295.520USD
-4.640-1.55%
Fechamento 07/11, 16:00（ET）Cotações atrasadas em 15 min
13.32BValor de mercado
11.00P/L TTM
Mais detalhes de United Therapeutics Corp Empresa
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Informações da empresa
Código da empresaUTHR
Nome da EmpresaUnited Therapeutics Corp
Data de listagemJun 17, 1999
Fundado em1996
CEODr. Martine A. Rothblatt
Número de funcionários1305
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 17
Endereço1000 Spring St
CidadeSILVER SPRING
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal20910
Telefone13016089292
Sitehttps://www.unither.com/
Código da empresaUTHR
Data de listagemJun 17, 1999
Fundado em1996
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
-0.06%
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
19.38K
+11.27%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
4.88K
-11.67%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+2.76%
Mr. Christopher Patusky, J.D.
Mr. Christopher Patusky, J.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
2.00K
-0.20%
Gov. Thomas G. (Tommy) Thompson, J.D.
Gov. Thomas G. (Tommy) Thompson, J.D.
Independent Director
Independent Director
--
--
Mr. Christopher A. Causey
Mr. Christopher A. Causey
Independent Director
Independent Director
--
--
Mr. James C. Edgemond
Mr. James C. Edgemond
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Martine A. Rothblatt
Dr. Martine A. Rothblatt
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
666.42K
-0.06%
Mr. Paul A. Mahon, J.D.
Mr. Paul A. Mahon, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
36.78K
--
Mr. Richard A. Giltner
Mr. Richard A. Giltner
Independent Director
Independent Director
19.38K
+11.27%
Prof. Nilda Mesa, J.D.
Prof. Nilda Mesa, J.D.
Independent Director
Independent Director
4.88K
-11.67%
The Hon. Dr. Louis W. Sullivan, M.D.
The Hon. Dr. Louis W. Sullivan, M.D.
Independent Director
Independent Director
3.20K
--
Mr. Michael Benkowitz
Mr. Michael Benkowitz
President, Chief Operating Officer
President, Chief Operating Officer
2.65K
+2.76%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
749.60M
94.36%
Rest of World
44.80M
5.64%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
9.93%
The Vanguard Group, Inc.
9.84%
Avoro Capital Advisors LLC
5.93%
State Street Global Advisors (US)
4.95%
Renaissance Technologies LLC
4.67%
Other
64.69%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
9.93%
The Vanguard Group, Inc.
9.84%
Avoro Capital Advisors LLC
5.93%
State Street Global Advisors (US)
4.95%
Renaissance Technologies LLC
4.67%
Other
64.69%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
48.91%
Investment Advisor
36.17%
Hedge Fund
7.48%
Pension Fund
4.28%
Individual Investor
1.75%
Research Firm
1.52%
Bank and Trust
1.46%
Sovereign Wealth Fund
1.23%
Insurance Company
0.12%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
1315
46.61M
103.33%
-1.16M
2025Q1
1369
46.67M
103.49%
-1.81M
2024Q4
1344
46.07M
102.60%
-3.00M
2024Q3
1278
45.38M
101.97%
-7.63M
2024Q2
1219
48.02M
108.26%
-2.92M
2024Q1
1151
47.12M
106.59%
-2.41M
2023Q4
1127
46.52M
99.01%
-2.26M
2023Q3
1094
46.35M
98.80%
-3.96M
2023Q2
1068
46.82M
99.96%
-3.45M
2023Q1
1055
47.11M
101.08%
-1.09M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
4.48M
9.93%
+12.87K
+0.29%
Mar 31, 2025
The Vanguard Group, Inc.
4.44M
9.84%
+15.26K
+0.34%
Mar 31, 2025
Avoro Capital Advisors LLC
2.67M
5.93%
-85.30K
-3.09%
Mar 31, 2025
State Street Global Advisors (US)
2.23M
4.95%
+30.71K
+1.40%
Mar 31, 2025
Renaissance Technologies LLC
2.11M
4.67%
+17.60K
+0.84%
Mar 31, 2025
Wellington Management Company, LLP
2.03M
4.49%
-437.48K
-17.76%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.22M
2.71%
+85.70K
+7.53%
Mar 31, 2025
Fidelity Management & Research Company LLC
1.03M
2.29%
-283.67K
-21.55%
Mar 31, 2025
AQR Capital Management, LLC
908.45K
2.01%
-67.00K
-6.87%
Mar 31, 2025
LSV Asset Management
902.32K
2%
-6.40K
-0.70%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
Invesco Biotechnology & Genome ETF
4.75%
First Trust NASDAQ Pharmaceuticals ETF
4.03%
Franklin Genomic Advancements ETF
3.58%
First Trust NYSE Arca Biotechnology Index Fund
3.56%
Formidable Fortress ETF
3.1%
Inspire Faithward Mid Cap Momentum ETF
2.83%
Invesco Pharmaceuticals ETF
2.66%
SPDR S&P Biotech ETF
2.62%
ERShares Entrepreneurs ETF
2.41%
Alger Russell Innovation ETF
2.18%
Ver Mais
Invesco Biotechnology & Genome ETF
Proporção4.75%
First Trust NASDAQ Pharmaceuticals ETF
Proporção4.03%
Franklin Genomic Advancements ETF
Proporção3.58%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.56%
Formidable Fortress ETF
Proporção3.1%
Inspire Faithward Mid Cap Momentum ETF
Proporção2.83%
Invesco Pharmaceuticals ETF
Proporção2.66%
SPDR S&P Biotech ETF
Proporção2.62%
ERShares Entrepreneurs ETF
Proporção2.41%
Alger Russell Innovation ETF
Proporção2.18%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
